{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T13:36:10Z","timestamp":1774186570023,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02970-7","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T18:01:56Z","timestamp":1713031316000},"page":"757-766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention"],"prefix":"10.1007","volume":"57","author":[{"given":"Angelo","family":"Silverio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Bellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Scudiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Attisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Centore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Maiellaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iacopo","family":"Muraca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Personeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Vecchione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Galasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"issue":"6","key":"2970_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","volume":"14","author":"F Franchi","year":"2017","unstructured":"Franchi F, Rollini F, Angiolillo DJ (2017) Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 14(6):361\u2013379. https:\/\/doi.org\/10.1038\/nrcardio.2017.18","journal-title":"Nat Rev Cardiol"},{"key":"2970_CR2","doi-asserted-by":"publisher","unstructured":"(1997) EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 18(10):1569\u201382. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a015136","DOI":"10.1093\/oxfordjournals.eurheartj.a015136"},{"key":"2970_CR3","doi-asserted-by":"publisher","unstructured":"Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ (2018) ACC\/AHA versus ESC guidelines on dual\u00a0antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol 72(23 Pt A):2915\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.057","DOI":"10.1016\/j.jacc.2018.09.057"},{"issue":"4","key":"2970_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10557-022-07322-2","volume":"37","author":"F Scudiero","year":"2023","unstructured":"Scudiero F, Canonico ME, Sanna GD et al (2023) Dual antiplatelet therapy with 3(rd) generation P2Y(12) inhibitors in STEMI patients: impact of body mass index on loading dose-response. Cardiovasc Drugs Ther 37(4):695\u2013703. https:\/\/doi.org\/10.1007\/s10557-022-07322-2","journal-title":"Cardiovasc Drugs Ther"},{"issue":"15","key":"2970_CR5","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","volume":"61","author":"G Parodi","year":"2013","unstructured":"Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61(15):1601\u20131606. https:\/\/doi.org\/10.1016\/j.jacc.2013.01.024","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2970_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.022125","volume":"10","author":"L De Luca","year":"2021","unstructured":"De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ (2021) Cangrelor: clinical data, contemporary use, and future perspectives. J Am Heart Assoc 10(13):e022125. https:\/\/doi.org\/10.1161\/jaha.121.022125","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"2970_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368(14):1303\u20131313. https:\/\/doi.org\/10.1056\/NEJMoa1300815","journal-title":"N Engl J Med"},{"issue":"6","key":"2970_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jama.297.6.591","volume":"297","author":"GW Stone","year":"2007","unstructured":"Stone GW, Bertrand ME, Moses JW et al (2007) Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA 297(6):591\u2013602. https:\/\/doi.org\/10.1001\/jama.297.6.591","journal-title":"JAMA"},{"issue":"21","key":"2970_CR9","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","volume":"360","author":"RP Giugliano","year":"2009","unstructured":"Giugliano RP, White JA, Bode C et al (2009) Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360(21):2176\u20132190. https:\/\/doi.org\/10.1056\/NEJMoa0901316","journal-title":"N Engl J Med"},{"issue":"3","key":"2970_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39(3):213\u2013260. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"2970_CR11","doi-asserted-by":"publisher","unstructured":"Byrne RA, Rossello X, Coughlan JJ et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. https:\/\/doi.org\/10.1093\/ehjacc\/zuad107","DOI":"10.1093\/ehjacc\/zuad107"},{"issue":"2","key":"2970_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119\u2013177. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"issue":"9867","key":"2970_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/s0140-6736(13)60108-7","volume":"381","author":"V Farooq","year":"2013","unstructured":"Farooq V, van Klaveren D, Steyerberg EW et al (2013) Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet (London, England) 381(9867):639\u2013650. https:\/\/doi.org\/10.1016\/s0140-6736(13)60108-7","journal-title":"Lancet (London, England)"},{"key":"2970_CR14","doi-asserted-by":"publisher","unstructured":"(1985) The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 312(14):932\u20136. https:\/\/doi.org\/10.1056\/nejm198504043121437","DOI":"10.1056\/nejm198504043121437"},{"issue":"21","key":"2970_CR15","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1161\/01.cir.103.21.2550","volume":"103","author":"CM Gibson","year":"2001","unstructured":"Gibson CM, de Lemos JA, Murphy SA et al (2001) Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 103(21):2550\u20132554. https:\/\/doi.org\/10.1161\/01.cir.103.21.2550","journal-title":"Circulation"},{"issue":"3","key":"2970_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1161\/01.cir.0000022691.71708.94","volume":"106","author":"A Poli","year":"2002","unstructured":"Poli A, Fetiveau R, Vandoni P et al (2002) Integrated analysis of myocardial blush and ST-segment elevation recovery after successful primary angioplasty: real-time grading of microvascular reperfusion and prediction of early and late recovery of left ventricular function. Circulation 106(3):313\u2013318. https:\/\/doi.org\/10.1161\/01.cir.0000022691.71708.94","journal-title":"Circulation"},{"issue":"12","key":"2970_CR17","doi-asserted-by":"publisher","first-page":"946","DOI":"10.2459\/jcm.0000000000000528","volume":"18","author":"C Baldi","year":"2017","unstructured":"Baldi C, Polito MV, Citro R et al (2017) Prognostic value of clinical, echocardiographic and angiographic indicators in patients with large anterior ST-segment elevation myocardial infarction as a first acute coronary event. J Cardiovasc Med (Hagerstown) 18(12):946\u2013953. https:\/\/doi.org\/10.2459\/jcm.0000000000000528","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"23","key":"2970_CR18","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/circulationaha.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123(23):2736\u20132747. https:\/\/doi.org\/10.1161\/circulationaha.110.009449","journal-title":"Circulation"},{"issue":"3","key":"2970_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1742-7843.2006.pto_293.x","volume":"98","author":"RJ Glynn","year":"2006","unstructured":"Glynn RJ, Schneeweiss S, St\u00fcrmer T (2006) Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 98(3):253\u2013259. https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_293.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"2970_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/pds.2098","volume":"20","author":"AR Patrick","year":"2011","unstructured":"Patrick AR, Schneeweiss S, Brookhart MA et al (2011) The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf 20(6):551\u2013559. https:\/\/doi.org\/10.1002\/pds.2098","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2970_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, White IR, Carlin JB et al (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393. https:\/\/doi.org\/10.1136\/bmj.b2393","journal-title":"BMJ"},{"issue":"3","key":"2970_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","volume":"5","author":"P Grimfj\u00e4rd","year":"2019","unstructured":"Grimfj\u00e4rd P, Lagerqvist B, Erlinge D, Varenhorst C, James S (2019) Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J Cardiovasc Pharmacother 5(3):151\u2013157. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz002","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"14","key":"2970_CR23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1161\/circulationaha.118.038317","volume":"139","author":"F Franchi","year":"2019","unstructured":"Franchi F, Rollini F, Rivas A et al (2019) Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 139(14):1661\u20131670. https:\/\/doi.org\/10.1161\/circulationaha.118.038317","journal-title":"Circulation"},{"issue":"1","key":"2970_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","volume":"16","author":"F Franchi","year":"2023","unstructured":"Franchi F, Ortega-Paz L, Rollini F et al (2023) Cangrelor in patients with coronary artery disease pretreated with ticagrelor: the switching antiplatelet (SWAP)-5 study. JACC Cardiovasc Interv 16(1):36\u201346. https:\/\/doi.org\/10.1016\/j.jcin.2022.10.034","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"2970_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ehjacc\/zuad041","volume":"12","author":"U Zeymer","year":"2023","unstructured":"Zeymer U, Lober C, Richter S et al (2023) Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and\/or with cardiogenic shock. Eur Heart J Acute Cardiovasc Care 12(7):462\u2013463. https:\/\/doi.org\/10.1093\/ehjacc\/zuad041","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"15","key":"2970_CR26","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.4244\/EIJ-D-22-00675","volume":"18","author":"P Kordis","year":"2023","unstructured":"Kordis P, Bozic Mijovski M, Berden J, Steblovnik K, Blinc A, Noc M (2023) Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: the CANGRELOR-OHCA study. EuroIntervention 18(15):1269\u20131271. https:\/\/doi.org\/10.4244\/EIJ-D-22-00675","journal-title":"EuroIntervention"},{"key":"2970_CR27","doi-asserted-by":"publisher","unstructured":"Baldi C, Silverio A, Esposito L et al (2021) Clinical outcome of patients with ST-elevation myocardial infarction and angiographic evidence of coronary artery ectasia. Catheter Cardiovasc Interv 99(2):340\u2013347.\u00a0https:\/\/doi.org\/10.1002\/ccd.29738","DOI":"10.1002\/ccd.29738"},{"key":"2970_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejim.2022.08.021","volume":"105","author":"G De Luca","year":"2022","unstructured":"De Luca G, Silverio A, Verdoia M et al (2022) Angiographic and clinical outcome of SARS-CoV-2 positive patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: a collaborative, individual patient data meta-analysis of six registry-based studies. Eur J Intern Med 105:69\u201376. https:\/\/doi.org\/10.1016\/j.ejim.2022.08.021","journal-title":"Eur J Intern Med"},{"issue":"5","key":"2970_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/circulationaha.120.046928","volume":"142","author":"G Gargiulo","year":"2020","unstructured":"Gargiulo G, Esposito G, Avvedimento M et al (2020) Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial. Circulation 142(5):441\u2013454. https:\/\/doi.org\/10.1161\/circulationaha.120.046928","journal-title":"Circulation"},{"issue":"13","key":"2970_CR30","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1161\/circulationaha.120.050205","volume":"143","author":"DJ Angiolillo","year":"2021","unstructured":"Angiolillo DJ, Bhatt DL, Stone GW (2021) Letter by Angiolillo et al regarding article, \u201cCangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS FASTER trial.\u201d Circulation 143(13):e795\u2013e796. https:\/\/doi.org\/10.1161\/circulationaha.120.050205","journal-title":"Circulation"},{"issue":"2","key":"2970_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/jamacardio.2016.4556","volume":"2","author":"M Vaduganathan","year":"2017","unstructured":"Vaduganathan M, Harrington RA, Stone GW et al (2017) Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb\/IIIa inhibitors: an exploratory analysis from the CHAMPION Trials. JAMA Cardiol 2(2):127\u2013135. https:\/\/doi.org\/10.1001\/jamacardio.2016.4556","journal-title":"JAMA Cardiol"},{"key":"2970_CR32","doi-asserted-by":"publisher","unstructured":"Yerasi C, Case BC, Chezar-Azerrad C et al (2021) Cangrelor vs. glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention. Am Heart J 238:59\u201365. https:\/\/doi.org\/10.1016\/j.ahj.2021.04.013","DOI":"10.1016\/j.ahj.2021.04.013"},{"issue":"7","key":"2970_CR33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jcin.2019.10.062","volume":"13","author":"A Silverio","year":"2020","unstructured":"Silverio A, Buccheri S, Venetsanos D et al (2020) Percutaneous treatment and outcomes of small coronary vessels: a SCAAR report. JACC Cardiovasc Interv 13(7):793\u2013804. https:\/\/doi.org\/10.1016\/j.jcin.2019.10.062","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02970-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02970-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02970-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:13:25Z","timestamp":1720516405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02970-7"}},"subtitle":["A report from the INVEST-STEMI group"],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["2970"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02970-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"14 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional ethics committee of the University Hospital of Salerno and conforms to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients were informed of the nature and aims of the study and asked to sign an informed consent for the anonymous management of their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Dr. Luca Esposito received a research grant by the CardioPath program from the Federico II University of Naples, Italy. The other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}